AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma

Shares of AbbVie Inc. fell 0.8% in premarket trade Tuesday after the Food and Drug Administration placed a partial hold on all the company's clinical trials of venetoclax as a potential treatment for multiple myeloma.